Your browser doesn't support javascript.
loading
Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update.
Bischoff, Lindsay A; Ganly, Ian; Fugazzola, Laura; Buczek, Erin; Faquin, William C; Haugen, Bryan R; McIver, Bryan; McMullen, Caitlin P; Newbold, Kate; Rocke, Daniel J; Russell, Marika D; Ryder, Mabel; Sadow, Peter M; Sherman, Eric; Shindo, Maisie; Shonka, David C; Singer, Michael C; Stack, Brendan C; Wirth, Lori J; Wong, Richard J; Randolph, Gregory W.
Afiliación
  • Bischoff LA; Department of Medicine, Division of Endocrinology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Ganly I; Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Fugazzola L; Endocrine Oncology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy.
  • Buczek E; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • Faquin WC; Department of Otolaryngology Head and Neck Surgery, The University of Kansas, Kansas City.
  • Haugen BR; Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • McIver B; Department of Medicine, University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora.
  • McMullen CP; Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida.
  • Newbold K; Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida.
  • Rocke DJ; Thyroid Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Russell MD; Department of Otolaryngology Head and Neck Surgery, Weill Medical College, Cornell University, New York, New York.
  • Ryder M; Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston.
  • Sadow PM; Division of Endocrinology and Medical Oncology, Mayo Clinic, Rochester, Minnesota.
  • Sherman E; Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Shindo M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Shonka DC; Department of Otolaryngology-Head and Neck Surgery, Oregon Health & Science University, Portland.
  • Singer MC; Department of Otolaryngology-Head and Neck Surgery, University of Virginia Health System, Charlottesville.
  • Stack BC; Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health System, Detroit, Michigan.
  • Wirth LJ; Department of Otolaryngology-Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield.
  • Wong RJ; Departments of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston.
  • Randolph GW; Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York.
JAMA Otolaryngol Head Neck Surg ; 150(3): 265-272, 2024 03 01.
Article en En | MEDLINE | ID: mdl-38206595
ABSTRACT
Importance Oncocytic (Hürthle cell) thyroid carcinoma is a follicular cell-derived neoplasm that accounts for approximately 5% of all thyroid cancers. Until recently, it was categorized as a follicular thyroid carcinoma, and its management was standardized with that of other differentiated thyroid carcinomas. In 2022, given an improved understanding of the unique molecular profile and clinical behavior of oncocytic thyroid carcinoma, the World Health Organization reclassified oncocytic thyroid carcinoma as distinct from follicular thyroid carcinoma. The International Thyroid Oncology Group and the American Head and Neck Society then collaborated to review the existing evidence on oncocytic thyroid carcinoma, from diagnosis through clinical management and follow-up surveillance. Observations Given that oncocytic thyroid carcinoma was previously classified as a subtype of follicular thyroid carcinoma, it was clinically studied in that context. However, due to its low prevalence and previous classification schema, there are few studies that have specifically evaluated oncocytic thyroid carcinoma. Recent data indicate that oncocytic thyroid carcinoma is a distinct class of malignant thyroid tumor with a group of distinct genetic alterations and clinicopathologic features. Oncocytic thyroid carcinoma displays higher rates of somatic gene variants and genomic chromosomal loss of heterozygosity than do other thyroid cancers, and it harbors unique mitochondrial DNA variations. Clinically, oncocytic thyroid carcinoma is more likely to have locoregional (lymph node) metastases than is follicular thyroid carcinoma-with which it was formerly classified-and it develops distant metastases more frequently than papillary thyroid carcinoma. In addition, oncocytic thyroid carcinoma rarely absorbs radioiodine. Conclusions and Relevance The findings of this review suggest that the distinct clinical presentation of oncocytic thyroid carcinoma, including its metastatic behavior and its reduced avidity to radioiodine therapy, warrants a tailored disease management approach. The reclassification of oncocytic thyroid carcinoma by the World Health Organization is an important milestone toward developing a specific and comprehensive clinical management for oncocytic thyroid carcinoma that considers its distinct characteristics.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Adenoma Oxifílico / Adenocarcinoma Folicular Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: JAMA Otolaryngol Head Neck Surg Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Adenoma Oxifílico / Adenocarcinoma Folicular Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: JAMA Otolaryngol Head Neck Surg Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos